Replies to post #3841 on Momenta Pharmaceuticals, Inc. (MNTA)

[jbog]

Sodrock

Regardless of expense the FDA is not going compromise safety and create an even more expensive burden on the system.

The FDA wouldn't compromise safety because all the biosimilars would follow the somewhat limited clinical trial path that the EU is following. What I'm saying is that once an biosimilar becomes approved, the FDA or HHS would make it substitutable.